Cargando…

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer

Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borcoman, Edith, Santana dos Santos, Elizabeth, Genestie, Catherine, Pautier, Patricia, Lacroix, Ludovic, Caputo, Sandrine M., Cabaret, Odile, Guillaud-Bataille, Marine, Michels, Judith, Auguste, Aurelie, Leary, Alexandra, Rouleau, Etienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380272/ https://www.ncbi.nlm.nih.gov/pubmed/37511329 http://dx.doi.org/10.3390/ijms241411570

Ejemplares similares

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2018)

Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases
por: Caputo, Sandrine, et al.
Publicado: (2012)

brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish
por: Shive, Heather R., et al.
Publicado: (2014)

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
por: Kubelac, Paul, et al.
Publicado: (2020)

Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours
por: Genestie, Catherine, et al.
Publicado: (2019)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?
por: Gouy, Sebastien, et al.
Publicado: (2017)

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types
por: Gouy, Sebastien, et al.
Publicado: (2017)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients
por: Lee, Daphne SC, et al.
Publicado: (2012)

Cervical Cancer and Fertility-Sparing Treatment
por: Zaccarini, François, et al.
Publicado: (2021)

Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer
por: Caputo, Sandrine M., et al.
Publicado: (2018)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

HRness in Breast and Ovarian Cancers
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2020)

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2020)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
por: Carraro, Dirce Maria, et al.
Publicado: (2013)

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service
por: Matta, Bruna Palma, et al.
Publicado: (2022)

Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients
por: Kfoury, Maria, et al.
Publicado: (2023)

Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
por: Lazzari, Grazia, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

False negative rate at (18)F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology
por: Gouy, Sebastien, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Value of the loss of heterozygosity to BRCA1 variant classification
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2022)

An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition
por: Muller, Danièle, et al.
Publicado: (2011)

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis
por: Auguste, Aurélie, et al.
Publicado: (2020)

Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy
por: Holub, Katarzyna, et al.
Publicado: (2020)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
por: Kim, Jinyong, et al.
Publicado: (2023)

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
por: Jovelet, Cécile, et al.
Publicado: (2017)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)

Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
por: Hyder, Zerin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9k6i3iu2oidoagqkm917abrjl